Optimized methods for differentiation of cells into cells with hepatocyte progenitor phenotypes, cells produced by the methods, and methods of using the cells

• US 9,057,051 B2
• Filed: 10/31/2008
• Issued: 06/16/2015
• Est. Priority Date: 10/31/2008
• Status: Active Grant

• Current Assignee: Katholieke Universiteit Leuven
• Original Assignee: Katholieke Universiteit Leuven
• Inventors: Pauwelyn, Karen, Verfaillie, Catherine M.
• Primary Examiner(s): Singh, Anoop
• Assistant Examiner(s): Montanari, David A
• Application Number:
  US13/126,834
• Publication Number:
  US 20110287539A1
• Time in Patent Office: 2,419 Days
• Field of Search: 435/325, 435/377
• US Class Current: 1/1
• CPC Class Codes: C12N 2501/113 Acidic fibroblast growth factor (aFGF, FGF-1)
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/119 Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
• CPC Class Codes: C12N 2501/12 Hepatocyte growth factor [HGF]
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/16 Activin; Inhibin; Mullerian inhibiting substance
• CPC Class Codes: C12N 2501/415 Wnt; Frizzeled
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2506/03 from non-embryonic pluripotent stem cells
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/067 Hepatocytes
• CPC Class Codes: C12N 5/0696 Artificially induced pluripotent stem cells, e.g. iPS

Abstract

The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express hepatocyte phenotypes and hepatocyte progenitor phenotypes. More particularly, the invention relates to methods for culturing cells so that the cells are induced to differentiate into cells that express a definitive endodermal phenotype, a liver-committed endodermal phenotype, a hepatoblast phenotype, and hepatocyte phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of liver deficiency, liver metabolism studies, and liver toxicity studies.

Claims

1. A method for inducing cells to differentiate into cells that express a hepatocyte phenotype, said method comprising the steps of:

(a) culturing either mouse or human embryonic stem (ES) cells, mouse or human induced pluripotent stem (iPS) cells or mouse, rat, or human multipotent adult progenitor cells characterized in that the multipotent adult progenitor cells can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages but are not embryonic germ cells, embryonic stem cells, or germ cells, with about 5 ng/ml to about 500 ng/ml Wnt3a and about 10 ng/ml to about 1,000 ng/ml ActivinA, to obtain cells that express a definitive endoderm phenotype,

(b) then culturing the cells produced in step (a) with about 1 ng/ml to about 100 ng/ml bFGF and about 5 ng/ml to about 5 ng/ml to about 50 ng/ml BMP4, to obtain cells that express a liver committed endodermal phenotype,

(c) then culturing the cells produced in step (b) with about 5 ng/ml to about 500 ng/ml aFGF, about 1 ng/ml to about 100 ng/ml FGF4 and about 2.5 ng/ml to about 250 ng/ml FGF8b, to obtain cells that express a hepatoblast phenotype, and (d) then culturing the cells produced in step (c) with about 2 ng/ml to about 200 ng/ml HGF and about 10 ng/ml to about 1,000 ng/ml Follistatin, to obtain cells that express a hepatocyte phenotype.

2. The method of claim 1, wherein the cells are cultured in step (a) with about 50 ng/ml Wnt3a and about 100 ng/ml ActivinA.

3. The method of claim 1, wherein the cells are cultured in step (b) with about 10 ng/ml bFGF and about 50 ng/ml BMP4.

4. The method of claim 1, wherein the cells are cultured in step (c) with about 50 ng/ml aFGF, about 10 ng/ml FGF4and about 25 ng/ml FGF8b.

5. The method of claim 1, wherein the cells are cultured in step (d) with about 20 ng/ml HGF and about 100 ng/ml Follistatin.

6. The method of claim 1, wherein the cells are cultured at one or more steps in a medium containing a serum concentration ranging from 0% to about 2%.

7. The method of claim 1, wherein the cells are cultured at one or more steps in a medium containing about 10⁻

5 M to about 10<sup>−

10</sup> M dexamethasone.

8. The method of claim 1, wherein the cells are cultured at one or more steps for at least four days.

9. The method of claim 1, wherein the cells in step (a) are cultured for about six days, the cells in step (b) are cultured for about four days, the cells in step (c) are cultured for about four days, and the cells in step (d) are cultured for about seven days.

10. The method of any of claims 1-9, wherein the multipotent adult progenitor cells are derived from bone marrow.